NCT06648057 2026-03-18
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
Recruiting
Clinical Trials
11 trialsNCT06859684 2026-03-09
HAIC-quad
West China Hospital
Phase 2 Recruiting
NCT07070700 2025-08-12
CASTLE-ZS-02
Fudan University
Phase 2 Recruiting
NCT06643208 2025-06-26
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
Fujian Provincial Hospital
Recruiting
NCT05342194 2025-04-23
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT06208462 2025-03-03
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05010681 2025-02-27
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Fudan University
Phase 2 Recruiting
NCT05532059 2025-02-10
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06192797 2024-11-05
CCGLC-013
Tongji Hospital
Phase 2 Recruiting
NCT06505486 2024-07-17
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
NCT06298968 2024-07-03
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting